ColoCare Study - Colorectal Cancer Cohort

The ColoCare Consortium is a multicenter initiative establishing an international cohort of
colorectal cancer (CRC) patients for interdisciplinary studies of CRC prognosis and outcomes
with sites at the Fred Hutchinson Cancer Research Center, Seattle (Washington, USA), H. Lee
Moffitt Cancer Center and Research Institute, Tampa (Florida, USA), the University Hospital
Heidelberg (Germany), the Huntsman Cancer Institute (Utah, USA), the Cedars-Senai Medical
Center (California, USA), University of Washington St. Louis (Missouri, USA), and University
of Tennessee (Tennessee, USA).

Aims: The ColoCare Study investigates clinical outcomes, including disease-free and overall
survival, predictors of cancer recurrence, survival, health-related quality-of-life and
treatment toxicities. In addition, cross-sectional analyses of biomarkers and/or health
behaviors are undertaken.

Patients are recruited at baseline (time of first diagnosis) and followed for up to 5 years
at regular timepoints (3m, 6m, 12m, 24m, 36m, 48m, 60m). The cohort includes a comprehensive
collection of specimens and data.

Inclusion Criteria:

1. Age 18-89 years;

2. Men and Women

3. Newly-diagnosed colon or rectal cancer (stages I-IV); CRC in treatment (FHCRC and HCI)

4. English (FHCRC, Moffitt, HCI, Cedars-Senai, UW St. Louis, UT) or German (University
Hospital Heidelberg)-speaking;

5. mentally/physically able to consent and participate.

Exclusion Criteria:

- if one of the above in not fulfilled

- insufficient language or consent capacity